6 Undervalued Biotechnology & Medical Research Stocks for Tuesday, September 24
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Tuesday, September 24 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Commentary & Analysis
6 Undervalued Biotechnology & Medical Research Stocks for Thursday, November 02
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Thursday, November 02 based on AAII’s Stock Grades.Eunice Kim
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, June 27
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, June 27 based on AAII’s Stock Grades.Eunice Kim
Is Purple Biotech Ltd - ADR (PPBT) Stock a Good Investment?
Learn more about Purple Biotech Ltd - ADR's (PPBT) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | PPBT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.2 | $674.0 | 4% |
|
| Shares Out (Mil) | 2,172.2 | 43.9 | 97% |
|
| Institutional Ownership | 97.1% | 84.7% | 72% |
|
| Float (Mil) | 1,854.1 | 47.3 | 95% |
|
| Beta | -0.54 | 0.71 | 2% |
|
| Avg Daily Volume (000s) | 7,640 | 293 | 95% |
|
| Price Change (52-week) |
(86.1%) | 68.8% | 5% |
|
| Growth | PPBT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | 1.2% | (1.5%) | 41% |
|
| EPS (5yr) | 35.6% | 14.9% | 86 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.1%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($2.880) | ($5.730) | ($1.010) | |
| Month Ago EPS | ($1.730) | ($5.310) | ($0.880) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.730) | ($5.310) | ($0.880) | |
| Year/Year Chg | na | 21,122% | 1,789% | |
| Financials | PPBT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($25) | ($11) | 22% |
|
| EPS (TTM) | ($0.014) | ($0.700) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($7) | 22% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $4 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $0 | $575 | 3% |
|
| Valuation | PPBT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 198.00 | 2.80 | 100% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PPBT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (97.5%) | (24.6%) | 6% |
|
| ROE | (117.8%) | (21.4%) | 8% |
|
| Liabilities to Assets | 13.8% | 32.2% | 9% |
|
| F-Score | 3 | 3 | 18% |
|
Purple Biotech Ltd did not pass any screens on 9/2/2026.
